Publications by authors named "U F Omar"
Multiple sclerosis (MS) affects 2.8 million people worldwide. Although the cause is unknown, various risk factors might be involved.
View Article and Find Full Text PDFArticle Synopsis
- Cholestasis is a liver disorder caused by the buildup of toxic bile acids, leading to liver damage and inflammation, with few treatment options available, highlighting the need for new therapies.
- The study investigates the effects of Pirfenidone (PF), a drug known for treating lung fibrosis, in a mouse model of cholestatic liver injury induced by ANIT, finding that PF significantly reduces harmful liver enzymes and improves liver tissue damage.
- PF’s protective effects are linked to its ability to regulate key signaling pathways related to bile acid transport, inflammation, and oxidative stress, suggesting its potential as a therapeutic option for cholestasis-related liver injuries.
The current study explored the protective potential of kaempferol 3-sophoroside-7-glucoside (KSG) against acute lung injury (ALI). Pre-treatment with KSG effectively secured mice from ALI and showed similar efficaciousness to dexamethasone. KSG markedly increased the survival rate and alleviated lung pathological lesions induced by lipopolysaccharide (LPS).
View Article and Find Full Text PDFFulminant hepatic failure (FHF) is the terminal phase of acute liver injury, which is characterized by massive hepatocyte necrosis and rapid hepatic dysfunction in patients without preexisting liver disease. There are currently no therapeutic options for such a life-threatening hepatic failure except liver transplantation; therefore, the terminal phase of the underlying acute liver injury should be avoided. Tomatidine (TOM), asteroidal alkaloid, may have different biological activities, including antioxidant and anti-inflammatory effects.
View Article and Find Full Text PDF